VIENNA, May 7, 2025 /PRNewswire/ — Dr. Werner Lanthaler, Founder and CEO of Wlanholding GmbH, has been appointed Chairman of the Supervisory Board at aTENSION.life, a high-tech life science startup developing precision diagnostics for hypertension. The appointment comes as part of a USD 3 million seed financing round led by Wlanholding, with eQventure and VP Venture Partners as co-lead investors.
aTENSION.life’s proprietary ALDO+ technology platform makes advanced mass spectrometry-based diagnostics accessible to patients with uncontrolled hypertension. The company’s first product, ALDO+PA, screens for primary aldosteronism, a significantly underdiagnosed condition affecting 5-10% of all hypertensive patients.
“Every hypertension patient deserves an early and precise diagnosis leading to a targeted treatment. This funding brings us one step closer in making clinical mass spectrometry diagnostics available to everyone,” states Dr. Lanthaler regarding his appointment at aTENSION.life.
The investment aligns with Dr. Lanthaler’s strategic focus on transformative technologies in the life sciences sector. Through Wlanholding, he continues to identify and support innovative companies addressing significant healthcare challenges. The ALDO+PA test is currently available in Austria through a partnership with labors.at and is planned to roll out across DACH markets by 2026, with first customers already implementing the technology in Germany, Switzerland, and the US.
aTENSION.life’s innovative approach addresses a vast global market, with approximately 1.3 billion adults affected by hypertension and 720 million not receiving adequate treatment due to underdiagnosis of specific hypertension subtypes.
Dr. Lanthaler will provide strategic guidance to aTENSION.life’s newly announced management team: Bernhard Klemen (CEO), Marko Poglitsch (CSO), and Katharina Wieser (CBO).
About Wlanholding GmbH
Wlanholding GmbH is a Family Office focused on investments and advisory services in life science and high-tech driven sustainability companies. Led by Dr. Werner Lanthaler, former CEO of Evotec SE, Wlanholding supports passionate founders and management teams to transform innovative businesses into scalable organizations with global impact. For more information, visit https://wlanholding.com/
About aTENSION.life
aTENSION.life is transforming hypertension care by making advanced mass spectrometry diagnostics accessible to everyone. The company’s ALDO+ technology platform sets new standards in precision diagnostics for hypertension, enabling targeted therapies with just one blood sample. For more information, visit www.atension.life.
Media Contact:
Mag. Katharina Wieser
Wlanholding GmbH
Schönborngasse 4, 1080 Vienna
kw@wlanholding.com, +436769633045
www.wlanholding.com
SOURCE Wlanholding GmbH
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…